Biomerica Reports Fiscal 2023 Year End Results
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed…
Logistics
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal”;…
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal”;…
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights
– Combined full-year revenue and government support income increased 355% year-over-year – – Received guidance…
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights
– Combined full-year revenue and government support income increased 355% year-over-year – – Received guidance…
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg…
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results
Second Quarter 2023 Net Revenues Increased 62% to $23.4 Million Launched VLN® Sales in California,…
QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with…
Societal CDMO to Report Financial Results for Second Quarter 2023 on August 9, 2023
Webcast Scheduled for Wednesday, August 9, 2023, at 4:30 p.m. Eastern SAN DIEGO and GAINESVILLE,…
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
Live webcast fireside chat on Monday, August 7th at 1:00 PM ET ISELIN, N.J., Aug….
BioNTech Completes Acquisition of InstaDeep
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design…
BioNTech Completes Acquisition of InstaDeep
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design…
Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market
Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25…
Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market
Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25…
QIAGEN expands range of digital PCR kits and services for the biopharma industry
New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to…